5006802022-04-012022-06-305006802022-04-012022-06-30in-bse-fin:OtherExpenses1Member5006802022-04-012022-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15006802022-04-012022-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss2iso4217:INRiso4217:INRxbrli:shares500680PFIZERNAINE182A01018Pfizer LimitedEquity2022-04-012023-03-312022-08-052022-07-27INRCroresFirst quarterSingle segmentPharmaceuticals2022-08-0512:00:002022-08-0514:45:00Not applicable2022-04-012022-06-30UnauditedStandalone592900000018020000061092000009023000001740500000-4841000009220000003640000026510000092980000043120000001797200000-1363300000433900000262500000-15410000010840000003255000000000325500000-190000032360000000457500000107.117.11007.117.111.The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its Meeting held on August 05, 2022 and were approved and taken on record at the Meeting of the Board of Directors of the Company held on that date. <BR> <BR> 2.The financial results of the Company have been prepared in accordance with Indian Accounting Standards (‘Ind AS”) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time). <BR> <BR> 3. The financial results for the quarter ended June 30, 2022 have been subject to limited review by the statutory auditors of the Company. The limited review report does not contain any modifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company’s website - www.pfizerltd.co.in <BR> <BR> 4.Figures for the quarter ended March 31, 2022 represent the difference between the audited figures in respect of the full financial year and published figures of nine months ended December 31, 2021 which were subject to a limited review by the statutory auditors. <BR> <BR> Exceptional items for the quarter ended June 30, 2022 comprises of: <BR> a. Rs. 129.85 crore on account of Voluntary Retirement Scheme (VRS) <BR> b. Additional charge of Rs. 6.48 crore (net) on account of restructuring to drive business transformation <BR> <BR> 6.The Company had entered into a business transfer agreement (BTA) with Mylan Pharmaceuticals Private Limited (Mylan) on September 30, 2021 to transfer certain primarily off-patented and generic established medicines business (Upjohn Business) as a going concern for a consideration of Rs.180.48 crore. Completion of transaction was subject to fulfillment of certain conditions as set out in the BTA. <BR> <BR> Mylan has received the requisite regulatory approvals and both the parties (being the Company and Mylan) have completed the conditions precedents set out in the BTA. Accordingly, the Company has received the purchase consideration of Rs. 180.48 crore from Mylan and the Company has transferred its Upjohn Business comprising of six brands which included Lyrica, Viagra, Celebrex, Amlogard, Daxid and Dilantin along with related business assets and liabilities to Mylan, effective August 1, 2022. <BR> <BR> Given that the closing conditions have been fulfilled post June 30, 2022 and transaction concluded on August 1, 2022, gain from the transaction shall be accounted for in the September 2022 quarter. <BR> <BR> 7.The Company has only one segment which is ‘Pharmaceuticals’. Therefore disclosure relating to segments is not applicable and accordingly not made.Other Expenses929800000Items that will not be reclassified subsequently to profit or loss-2600000Other comprehensive income, net of taxes0-2600000-7000000